Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

about

Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Item

http://www.wikidata.org/entity/Q38957078

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Buccal viral DNA as a trigger ...... he mousepox model of smallpox.

@en

type

Item

label

Buccal viral DNA as a trigger ...... he mousepox model of smallpox.

@en

prefLabel

Buccal viral DNA as a trigger ...... he mousepox model of smallpox.

@en

P1476

Buccal viral DNA as a trigger ...... he mousepox model of smallpox.

@en

P2093

Maria Korom

http://www.w3.org/2001/XMLSchema#string

R Mark Buller

http://www.w3.org/2001/XMLSchema#string

Ryan Crump

http://www.w3.org/2001/XMLSchema#string

Scott Parker

http://www.w3.org/2001/XMLSchema#string

P2860

Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus.

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans

Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.

Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients.

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

P304

112-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ANTIVIRAL.2016.12.015

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28039021

http://www.w3.org/2001/XMLSchema#string

P921

Baztanga

P932

5291782

http://www.w3.org/2001/XMLSchema#string